Is mPGES-1 a promising target for pain therapy?

Klaus Scholich; Gerd Geisslinger

doi:10.1016/j.tips.2006.06.001

Is mPGES-1 a promising target for pain therapy?

Trends Pharmacol Sci. 2006 Aug;27(8):399-401. doi: 10.1016/j.tips.2006.06.001. Epub 2006 Jun 30.

Authors

Klaus Scholich¹, Gerd Geisslinger

Affiliation

¹ Pharmazentrum Frankfurt, ZAFES, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany. scholich@em.uni-frankfurt.de

PMID: 16815559
DOI: 10.1016/j.tips.2006.06.001

Abstract

Cyclooxygenase (COX) inhibitors are widely used analgesic and anti-inflammatory drugs. Owing to undesirable effects caused by unselective COX inhibitors and selective COX-2 inhibitors, microsomal prostaglandin E(2) synthase-1 has been considered as an alternative target for the development of analgesic drugs. However, recent findings question the usefulness of this terminal synthase as a promising drug target for pain therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cyclooxygenase Inhibitors / pharmacology
Cyclooxygenase Inhibitors / therapeutic use*
Humans
Intramolecular Oxidoreductases / antagonists & inhibitors*
Intramolecular Oxidoreductases / metabolism
Models, Biological
Pain / drug therapy*
Pain / enzymology
Prostaglandin-E Synthases

Substances

Cyclooxygenase Inhibitors
Intramolecular Oxidoreductases
PTGES protein, human
Prostaglandin-E Synthases